NATIONAL CENTRE FOR NUCLEAR RESEARCH, Poland Report issue

Academic/Hospital Phase 1

Organization Overview

First Clinical Trial
2016
NCT03246659
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2016

Timeline

NOW
  • Now

Alternative names

NATIONAL CENTRE FOR NUCLEAR RESEARCH, Poland

Active Ingredients

Drugs in Phase 1 Trials (2)

111in-cp04 (1 trial)

gelofusin (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Carcinoma (Phase 1)

Carcinoma, Neuroendocrine (Phase 1)

Thyroid Diseases (Phase 1)

Thyroid Neoplasms (Phase 1)

Overview

  • Highest Phase: Phase 1
  • # of Trials: 1
  • # of Trial APIs: 2